Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GRI Bio, Inc. (NASDAQ: GRI) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-generated highlights to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on NKT cell modulators for inflammatory, fibrotic and autoimmune diseases, GRI Bio uses its filings to report on clinical progress, financing transactions, governance matters and risk factors relevant to GRI stock.
Among the most informative documents are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, pipeline programs such as GRI-0621 for idiopathic pulmonary fibrosis and type 2 dNKT agonists for systemic lupus erythematosus, and its status as a smaller reporting and emerging growth company. These filings also summarize key agreements, intellectual property and the broader risk profile associated with clinical-stage drug development.
GRI Bio’s Form 8-K current reports highlight material events, including:
- Topline and interim data from the Phase 2a GRI-0621-IPF-02 trial in IPF, covering safety, biomarker changes, alveolar basement membrane repair markers and forced vital capacity (FVC) analyses.
- Details of public offerings of common stock, pre-funded warrants and Series F warrants, including purchase agreements, warrant terms and expected use of proceeds.
- Corporate actions such as amendments to the 2018 Equity Incentive Plan and annual meeting voting results.
On this page, users can also review registration statements on Form S-1 and amendments, which outline securities offerings and include extensive exhibit lists covering warrants, purchase agreements and other contracts. Proxy statements (DEF 14A) provide insight into board structure, compensation plans and shareholder proposals.
Stock Titan’s interface surfaces AI-powered summaries of lengthy filings to explain key points in plain language, such as how a financing may affect capital structure or how reported IPF trial data relate to GRI-0621’s development. Real-time updates from EDGAR ensure new 10-K, 10-Q, 8-K, S-1 and related forms appear promptly, while dedicated sections for insider and beneficial ownership information can be explored through the company’s broader filing history.
Use this GRI filings hub to quickly locate and interpret the regulatory documents that shape the investment narrative around GRI Bio’s NKT cell–focused pipeline and its Nasdaq-listed common stock.
GRI Bio, Inc. director David Charles Baker was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option is exercisable with a vesting schedule of four equal quarterly installments and becomes fully vested on the first anniversary of the grant. The option expires on 08/13/2035. Following the grant, Mr. Baker beneficially owns 4,527 derivative shares on a direct basis. The Form 4 was signed by an attorney-in-fact, Leanne Kelly, on 08/14/2025.
Roelof Rongen, a director of GRI Bio, Inc. (GRI), was granted a stock option to buy 4,527 shares of common stock at an exercise price of $1.30 per share on 08/13/2025. The option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date, with an exercise/expiration schedule showing exercisability beginning 08/13/2025 and an expiration date of 08/13/2035. Following the grant, Mr. Rongen directly beneficially owns 4,527 underlying shares/options. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 08/14/2025.
GRI Bio, Inc. director David Leslie Szekeres received a stock option grant on 08/13/2025 to purchase 7,545 shares of common stock. The Form 4 shows the derivative award is a stock option with a stated $1.30 conversion/exercise price and an expiration date of 08/13/2035. The option was reported as acquired on 08/13/2025 and is held directly. The award vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date, per the filing. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
GRI Bio is a clinical-stage biopharmaceutical company advancing oral iNKT/dNKT modulators. The company reported a net loss of $2.89 million for the quarter and $5.94 million for the six months ended June 30, 2025, driven by higher research and development spending on GRI-0621 ($1.88 million in Q2; $3.52 million six months) and ongoing company overhead.
Cash and cash equivalents were $5.12 million at period end; management forecasts this funding will support operations into the fourth quarter of 2025 but discloses substantial doubt about going concern without additional financing. Clinical progress includes completion of Phase 2a enrollment in July 2025, an Independent Data Monitoring Committee review reporting no safety concerns for early cohorts, and topline biomarker results expected in Q3 2025. Recent financings include an April 2025 offering (net $4.02 million) and ATM sales (net $4.29 million through June 30, 2025). The company disclosed a material weakness in internal controls.
GRI Bio, Inc. filed a Form S-8 to register an additional 400,000 shares of common stock reserved for issuance under its Amended and Restated 2018 Equity Incentive Plan. The filing incorporates prior Form S-8 registrations by reference and includes the amended plan and related award agreement forms as exhibits. The registration increases the pool available for employee stock awards but does not disclose total shares outstanding or quantify potential dilution.
GRI Bio, Inc. reported results from its August 13, 2025 virtual Annual Meeting. Stockholders approved an amendment to the Amended and Restated 2018 Equity Incentive Plan, increasing the number of shares reserved for issuance by 400,000 shares. The company noted 2,496,800 shares issued and outstanding as of the July 8, 2025 record date and a quorum of 1,090,373 shares (approximately 43.67%) was present or represented.
At the meeting the board nominees Roelof Rongen and Camilla V. Simpson were elected with 63,031 and 63,581 votes for, respectively, and the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal 2025 was ratified with 1,072,167 votes for. Exhibit 10.1 contains the amended equity incentive plan text.
GRI Bio (Nasdaq: GRI) furnished an 8-K under Item 7.01 disclosing a press release that reports interim safety results from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis. The disclosure is provided solely for Regulation FD purposes and is expressly not deemed “filed” under the Exchange Act. No efficacy data, financial metrics, or guidance updates were included. Exhibit 99.1 contains the full press release; no other material items were reported.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
